Long-term Outcomes and Prognosis in New-Onset Psoriasis | Dermatology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Long-term Outcomes and Prognosis in New-Onset Psoriasis

Educational Objective
To describe the clinical course and identify possible indicators of long-term outcomes in psoriasis.
1 Credit CME
Key Points

Question  What are the prognostic factors for the clinical course of psoriasis?

Findings  In this 10-year cohort study of 721 patients with recent-onset psoriasis, 52% of the patients with plaque phenotype, high disease activity, and scalp lesions developed severe disease, compared with 11% of patients with low disease activity at inclusion.

Meaning  Patient characteristics at onset can help to estimate the long-term course of psoriasis with good discriminatory power.

Abstract

Importance  Psoriasis is a heterogeneous disease. Improved understanding of prognosis and long-term outcomes in new-onset psoriasis may improve care.

Objective  To describe the clinical course of psoriasis and identify possible indicators of long-term outcomes.

Design, Setting, and Participants  The Stockholm Psoriasis Cohort was a noninterventional inception cohort study enrolling patients between 2001 and 2005. The present study was conducted from January 15, 2019, to February 5, 2021. At enrollment and 10 years, patients were examined by dermatologists and rheumatologists. Data from examinations were complemented by questionnaires, medical records, and registers. A total of 721 patients with recent-onset psoriasis (<12 months duration), 15 years or older were recruited using advertising and referrals from a broad range of health care settings.

Main Outcomes and Measures  Disease severity and psoriatic arthritis (PsA). Recursive partitioning and regression models were implemented to identify probable indicators of long-term outcomes.

Results  A total of 721 patients (median [interquartile range] age, 39 [27-55] years; 405 [56%] women), including 542 (75%) with plaque-onset and 174 (24%) with guttate-onset psoriasis, were enrolled. The median follow-up was 9.6 years (interquartile range, 8.8-10.4 years). The cumulative incidence of severe psoriasis at 12 years from enrollment was 21%. Among 509 patients examined clinically after 10 years, 77 of 389 patients (20%) with plaque onset and 56 of 116 (48%) with guttate onset had minimal disease activity without treatment, and 120 of 509 (24%) had PsA. Recursive partitioning identified strata with distinct risks for severe skin disease and PsA: the cumulative incidence of severe disease in patients with plaque phenotype, above-median disease activity, and scalp lesions was 52% (95% CI, 41%-64%), compared with 11% (95% CI, 8%-14%) in patients with below-median disease activity at inclusion; and 48 of 82 patients (59%) with peripheral enthesitis had PsA after 10 years compared with 37 of 304 patients (12%) without initial joint pain (P < .001). Smoking (hazard ratio, 1.70; 95% CI, 1.10-2.63) and activating genes in the interleukin-23 (IL-23) pathway (odds ratio, 1.55; 95% CI, 1.14-2.11) were also significantly associated with a severe disease course. Systemic therapy at or before enrollment was associated with a lower risk for severe disease at 10 years compared with later initiation of systemic therapy (odds ratio, 0.24; 95% CI, 0.06-0.90).

Conclusions and Relevance  The findings of this cohort study suggest that combinations of clinical characteristics at onset and activating genes in the IL-23 pathway are significantly associated with the clinical course of psoriasis, whereas joint pain and peripheral enthesitis may indicate the probability of PsA. Patients within those categories merit specialist referral and closer follow-up. The possibility of modifying the disease course with early systemic intervention should be tested.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: February 23, 2021.

Published Online: April 14, 2021. doi:10.1001/jamadermatol.2021.0734

Corresponding Author: Mona Ståhle, MD, B2:01, Division of Dermatology and Venereology, Department of Medicine, Karolinska Universitetssjukhuset, Solna 171 76 Stockholm, Sweden (mona.stahle@ki.se).

Author Contributions: Mr Svedbom and Dr Ståhle had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Larsson, Lindqvist, Ståhle.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Svedbom, Ståhle.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Svedbom.

Obtained funding: Ståhle.

Administrative, technical, or material support: Nikamo, Wolk, Kjellman, Eidsmo, Lindqvist, Ståhle.

Supervision: Lindqvist, Ståhle.

Conflict of Interest Disclosures: Mr Svedbom is an employee of ICON Clinical Research, a contract research organization. Dr Mallbris is an employee of Eli Lilly and Company. Dr Ståhle has consulting agreements involving financial compensation with Eli Lilly and Company, AbbVie, Janssen, Leo Pharma, BMS, and Novartis. No other disclosures were reported.

Funding/Support: This study was funded by the Stockholm County Council, the Swedish Medical Research Council, Hudfonden, and the Swedish Psoriasis Association.

Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank the pictured patients for granting permission to publish this information. We are also grateful to the patients for participating, Eva Vingård, PhD (Department of Medical Science, Uppsala University), for input on the clinical research forms, and Maria Lundqvist, BS, and Susanne Bergqvist, BS (Department of Dermatology Karolinska University Hospital), for supporting study operations.

References
1.
WHO.  Global Report on Psoriasis. World Health Organization;2016.
2.
Nestle  FO , Kaplan  DH , Barker  J .  Psoriasis.   N Engl J Med. 2009;361(5):496-509. doi:10.1056/NEJMra0804595 PubMedGoogle ScholarCrossref
3.
Icen  M , Crowson  CS , McEvoy  MT , Dann  FJ , Gabriel  SE , Maradit Kremers  H .  Trends in incidence of adult-onset psoriasis over three decades: a population-based study.   J Am Acad Dermatol. 2009;60(3):394-401. doi:10.1016/j.jaad.2008.10.062 PubMedGoogle ScholarCrossref
4.
Griffiths  CE , Christophers  E , Barker  JN ,  et al.  A classification of psoriasis vulgaris according to phenotype.   Br J Dermatol. 2007;156(2):258-262. doi:10.1111/j.1365-2133.2006.07675.x PubMedGoogle ScholarCrossref
5.
Boehncke  WH , Schön  MP .  Psoriasis.   Lancet. 2015;386(9997):983-994. doi:10.1016/S0140-6736(14)61909-7 PubMedGoogle ScholarCrossref
6.
Ryan  C , Korman  NJ , Gelfand  JM ,  et al.  Research gaps in psoriasis: opportunities for future studies.   J Am Acad Dermatol. 2014;70(1):146-167. doi:10.1016/j.jaad.2013.08.042 PubMedGoogle ScholarCrossref
7.
Strober  BE , Griffiths  CE , O’Dell  SJ , Tebbey  PW , Barker  JN ; International Psoriasis Council.  Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise.   Br J Dermatol. 2016;174(1):212-215. doi:10.1111/bjd.13980 PubMedGoogle ScholarCrossref
8.
Barker  J , Kimball  AB , Tebbey  PW , Sterry  W .  A strategic approach to setting the research agenda in psoriasis.   Psoriasis Forum. 2011;17(2):97-102. doi:10.1177/247553031117a00202 Google ScholarCrossref
9.
Ludvigsson  JF , Andersson  E , Ekbom  A ,  et al.  External review and validation of the Swedish National Inpatient Register.   BMC Public Health. 2011;11:450. doi:10.1186/1471-2458-11-450 PubMedGoogle ScholarCrossref
10.
Wettermark  B , Hammar  N , Fored  CM ,  et al.  The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months.   Pharmacoepidemiol Drug Saf. 2007;16(7):726-735. doi:10.1002/pds.1294 PubMedGoogle ScholarCrossref
11.
Ludvigsson  JF , Almqvist  C , Bonamy  AK ,  et al.  Registers of the Swedish total population and their use in medical research.   Eur J Epidemiol. 2016;31(2):125-136. doi:10.1007/s10654-016-0117-yPubMedGoogle ScholarCrossref
12.
Mallbris  L , Larsson  P , Bergqvist  S , Vingård  E , Granath  F , Ståhle  M .  Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases.   J Invest Dermatol. 2005;124(3):499-504. doi:10.1111/j.0022-202X.2004.23611.x PubMedGoogle ScholarCrossref
13.
Christophers  E , Sterry  W. Psoriasis. In: Fitzpatrick TB, Elsen AZ, Wolff K, Freedberg IM Austen KF, eds. Dermatology in General Medicine. 4th ed. McGraw-Hill; 1993:489-514.
14.
Fredriksson  T , Pettersson  U .  Severe psoriasis—oral therapy with a new retinoid.   Dermatologica. 1978;157(4):238-244. doi:10.1159/000250839 PubMedGoogle ScholarCrossref
15.
Langley  RG , Ellis  CN .  Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system Physician’s Global Assessment.   J Am Acad Dermatol. 2004;51(4):563-569. doi:10.1016/j.jaad.2004.04.012 PubMedGoogle ScholarCrossref
16.
Egeberg  A , Nast  A .  A critical eye on registry data in psoriasis.   Br J Dermatol. 2017;177(1):245-246. doi:10.1111/bjd.15309 PubMedGoogle ScholarCrossref
17.
Svensson  B , Holmström  G , Lindqvist  U ; Psoriatric Arthritis Register Group of the Swedish Society for Rheumatology.  Development and early experiences of a Swedish psoriatic arthritis register.   Scand J Rheumatol. 2002;31(4):221-225. doi:10.1080/030097402320318413 PubMedGoogle ScholarCrossref
18.
Taylor  W , Gladman  D , Helliwell  P , Marchesoni  A , Mease  P , Mielants  H ; CASPAR Study Group.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study.   Arthritis Rheum. 2006;54(8):2665-2673. doi:10.1002/art.21972 PubMedGoogle ScholarCrossref
19.
Nikamo  P , Lysell  J , Ståhle  M .  Association with genetic variants in the IL-23 and NF-κB pathways discriminates between mild and severe psoriasis skin disease.   J Invest Dermatol. 2015;135(8):1969-1976. doi:10.1038/jid.2015.103 PubMedGoogle ScholarCrossref
20.
de Jong  EM .  The course of psoriasis.   Clin Dermatol. 1997;15(5):687-692. doi:10.1016/S0738-081X(97)00023-0 PubMedGoogle ScholarCrossref
21.
Fortes  C , Mastroeni  S , Leffondré  K ,  et al.  Relationship between smoking and the clinical severity of psoriasis.   Arch Dermatol. 2005;141(12):1580-1584. doi:10.1001/archderm.141.12.1580 PubMedGoogle ScholarCrossref
22.
Hägg  D , Eriksson  M , Sundström  A , Schmitt-Egenolf  M .  The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men.   PLoS One. 2013;8(5):e63619. doi:10.1371/journal.pone.0063619 PubMedGoogle Scholar
23.
Busse  K , Liao  W .  Which psoriasis patients develop psoriatic arthritis?   Psoriasis Forum. 2010;16(4):17-25. doi:10.1177/247553031016a00403 PubMedGoogle ScholarCrossref
24.
Eder  L , Polachek  A , Rosen  CF , Chandran  V , Cook  R , Gladman  DD .  The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort Study.   Arthritis Rheumatol. 2017;69(3):622-629. doi:10.1002/art.39973 PubMedGoogle ScholarCrossref
25.
Wilson  FC , Icen  M , Crowson  CS , McEvoy  MT , Gabriel  SE , Kremers  HM .  Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study.   Arthritis Rheum. 2009;61(2):233-239. doi:10.1002/art.24172 PubMedGoogle ScholarCrossref
26.
Menter  A .  Psoriasis and psoriatic arthritis treatment.   Am J Manag Care. 2016;22(8)(suppl):s225-s237.PubMedGoogle Scholar
27.
Ingram  JT .  The significance and management of psoriasis.   BMJ. 1954;2(4892):823-828. doi:10.1136/bmj.2.4892.823 PubMedGoogle ScholarCrossref
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close